survival data
J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025
Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy